GEMTESA SIGNIFICANTLY REDUCED
ALL 3 KEY OVERACTIVE BLADDER
SYMPTOMS AT 12 WEEKS1,2

Patient. GEMTESA® reduces key symptoms of overactive bladder.

Statistically significant reductions in average daily UUI episodes at 12 weeks (co-primary endpoint) vs placebo1,2*

Patients taking GEMTESA had ~60% least square (LS) mean reduction from baseline in UUI episodes at 12 weeks vs ~40% taking placebo (-2.0 vs -1.4, respectively)1

*Statistically significant improvement in UUI in the GEMTESA group vs placebo at week 12 (P<0.0001).1,2

Urge urinary incontinence (UUI)1,2

Graph showing reductions in urge urinary incontinence (UUI). Patients taking GEMTESA® had reductions in average daily UUI episodes at 12 weeks.

Patients taking GEMTESA had ~60% least square (LS) mean reduction from baseline in UUI episodes at 12 weeks vs ~40% taking placebo (-2.0 vs -1.4, respectively)1

*Statistically significant improvement in UUI in the GEMTESA group vs placebo at week 12 (P<0.0001).1,2

Statistically significant reductions in average daily micturition frequency at 12 weeks (co-primary endpoint) vs placebo1,2†

Patients taking GEMTESA had a ~16% LS mean reduction from baseline in micturition frequency vs ~11% with placebo (-1.8 vs -1.3, respectively)1

Statistically significant improvement in micturition frequency in the GEMTESA group vs placebo at week 12 (P<0.001).1,2

Please see 12-week study design above.

Micturition frequency1,2

Graph showing reductions in average daily micturition frequency at 12 weeks. Patients taking GEMTESA® had improvements in micturition frequency.

Patients taking GEMTESA had a ~16% LS mean reduction from baseline in micturition frequency vs ~11% with placebo (-1.8 vs -1.3, respectively)1

Statistically significant improvement in micturition frequency in the GEMTESA group vs placebo at week 12 (P<0.001).1,2

Urgency is the hallmark OAB symptom3,4

Approximately 60% of individuals with OAB symptoms
have urgency episodes without leakage5

Portable restroom.

Statistically significant reductions in average daily urgency episodes—need to urinate immediately—at 12 weeks (secondary endpoint) vs placebo1,2‡

At 12 weeks, ~43% of all OAB patients taking GEMTESA had a 50% reduction in urgency episodes vs placebo (~38%)

P=0.002 vs placebo.1,2

§Data were based on unadjusted values for a supportive outcome measure that was a prespecified secondary endpoint in the pivotal EMPOWUR trial.2

Please see 12-week study design above.

Urgency episodes1,2

Graph showing reductions in average daily urgency episodes. GEMTESA® features urgency data on its label.

At 12 weeks, ~43% of all OAB patients taking GEMTESA had a 50% reduction in urgency episodes vs placebo (~38%)

§Data were based on unadjusted values for a supportive outcome measure that was a prespecified secondary endpoint in the pivotal EMPOWUR trial.2

Reduction from baseline in average UUI episodes per 24 hours of at least 75% at week 12 vs placebo.

52.4% of patients taking GEMTESA experienced a 75% reduction in daily UUI episodes at 12 weeks vs 36.8% of patients on placebo.2‖

Data were based on unadjusted values for a supportive outcome measure that was a prespecified secondary endpoint in the pivotal EMPOWUR trial.2

UUI episodes1,2

Graph showing achievement of ≥75% reduction in daily urinary incontinence (UUI) episodes. 52% of GEMTESA® patients with OAB wet vs ~37% of placebo patients.

52.4% of patients taking GEMTESA experienced a 75% reduction in daily UUI episodes at 12 weeks vs 36.8% of patients on placebo.2‖

Data were based on unadjusted values for a supportive outcome measure that was a prespecified secondary endpoint in the pivotal EMPOWUR trial.2

But wait, there’s more!

GEMTESA is the first and only beta-3 agonist with
urgency data in its label1

Learn about the mechanism of action (MOA)
of GEMTESA

See MOA
Diagram of a bladder. Learn about the mechanism of action (MOA) of GEMTESA®.
 

References: 1. GEMTESA. Prescribing information. Urovant Sciences GmbH; 2020. Accessed January 4, 2021. https://gemtesa.com/sites/default/files/gemtesa-prescribing-information.pdf 2. Data on file. Urovant Sciences GmbH. 3. Zhou F, Newman DK, Palmer MH. Urinary urgency in working women: what factors are associated with urinary urgency progression? J Womens Health. 2018;27(5):575-583. doi:10.1089/jwh.2017.6555 4. Salvatore S, Espuña- Pons M, Tubaro A. Urinary urgency: a symptom in need of a cure. Res Rep Urol. 2019;11:327-331. doi:10.2147/RRU.S216757 5. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336. doi:10.1007/s00345-002-0301-4